Xperix Unveils Vision for AI-Based Obesity Digital Convergence Drug at APEC

Artificial intelligence (AI) solutions company Xperix unveiled its AI-based obesity digital convergence drug pipeline and global vision at the "K-Medical AI Innovation Summit," a side event of the "15th APEC High-Level Meeting on Health and the Economy," held at the Shilla Hotel in Seoul on September 16, 2025. Previously, Xperix had formalized its entry into the AI healthcare business by acquiring management rights of Bagel Labs, which is jointly developing an obesity digital convergence drug with Hanmi Pharmaceutical.

This meeting was the first ministerial-level APEC health and economic conference held in Korea, attended by more than 480 participants, including health and economic policy officials from 21 member countries, representatives from international organizations, and business leaders, who discussed global health agendas such as digital health, healthy aging, and mental health. Xperix’s digital convergence drug was introduced as a leading example of medical AI innovation in Korea.

Park Suhong, Chief AI Officer (CAIO) of Xperix, gave a presentation titled "AI-Based Personalized Obesity Treatment: The Convergence of GLP-1 and Digital Therapeutics." Park pointed out, "While GLP-1 is effective for weight loss, it has clear limitations such as loss of muscle mass, high dropout rates, and rebound weight gain."

He continued, "Citing studies published in international journals, when lifestyle improvements are combined, the effect on weight loss increases by more than three times, and the reduction in waist circumference is more than five times greater." He emphasized, "Xperix’s AI platform optimizes scientifically validated treatment methods for each individual, thereby maximizing both treatment effectiveness and patient adherence."

Bagel Labs, whose management rights were acquired by Xperix, is currently co-developing the industry’s first obesity digital convergence drug with Hanmi Pharmaceutical. This product is an innovative therapy that combines Hanmi Pharmaceutical’s next-generation GLP-1 new drug, Efpeglenatide, with Xperix’s AI-DTx platform.

Xperix’s AI-DTx platform integrates with various digital devices, such as continuous glucose monitors (CGM) and body composition analyzers, to analyze patient data in real time. Based on this, it provides personalized diet and exercise programs, enhancing both treatment effectiveness and patient compliance.

In particular, this convergence treatment model is supported by Korea’s "Digital Medical Product Act," the world’s first legislation of its kind, which provides the institutional foundation to approve and prescribe new drugs and digital therapeutics as a single integrated pharmaceutical product. Through this platform, Xperix is demonstrating that digital healthcare can move beyond being a mere supplementary tool to become an equally innovative area alongside new drug development.

Park Suhong, CAIO, stated, "We aim to present a new treatment paradigm based on scientific evidence, going beyond simply combining new drugs and digital therapeutics," and added, "Through joint research and regulatory harmonization with APEC member countries, we will establish the global standard for chronic disease treatment."